Landscapes / Cell therapy
In vivo CAR-T landscape
16 drugs in 19 active trials · Every stage · updated 16 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs16
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
In vivo CD19 CAR-T, mRNA in lipid nanoparticles |
CREATE Medicines · Private |
Phase 1/2 | 1 Dec 2028Phase 1/2 trial completes | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 1 Dec 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Autoimmune Diseases, Systemic Lupus Erythematosus and 2 more | ||||
| Open drug page | |||||
In vivo CD19 CAR-T |
Phase 1 | Dec 2026Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Non-Hodgkin Lymphoma | ||||
| Open drug page | |||||
In vivo BCMA CAR-T |
Kelonia Therapeutics · Private |
Phase 1 | Mar 2027Phase 1 trial completes | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Multiple Myeloma in Relapse, Myeloma Multiple and 12 more | ||||
| Open drug page | |||||
In vivo CAR-T, mRNA in lipid nanoparticles, target not disclosed |
Early Phase 1 | 30 May 2027Early Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 30 May 2027 · Early Phase 1 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA) | ||||
| Open drug page | |||||
In vivo CD19 CAR-T, mRNA in CD8-targeted lipid nanoparticles |
Phase 1 | 31 May 2027Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 May 2027 · Phase 1 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Scleroderma and 2 more | ||||
| Open drug page | |||||
In vivo BCMA CAR-T |
Vyriad · Private |
Phase 1 | 31 Aug 2027Phase 1 trial completes | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | ||||
| Open drug page | |||||
In vivo BCMA CAR-T, lentiviral |
AstraZeneca +1 · Public AZN |
Early Phase 1 | 30 Nov 2027Early Phase 1 trial completes | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 30 Nov 2027 · Early Phase 1 trial completes | ||||
| Also tested for | Relapsed/ Refractory Multiple Myeloma | ||||
| Open drug page | |||||
In vivo CD19 CAR-T, mRNA in T-cell-targeted lipid nanoparticles |
AbbVie · Public ABBV |
Phase 1 | Nov 2027Phase 1 trial completes | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | Nov 2027 · Phase 1 trial completes | ||||
| Also tested for | Rheumatoid Arthritis, Systemic Lupus Erythematosus | ||||
| Open drug page | |||||
In vivo CD19 CAR, circular RNA in targeted lipid nanoparticles |
Phase 1 | 19 Dec 2027Early Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 19 Dec 2027 · Early Phase 1 trial completes | ||||
| Also tested for | Relapsed/Refractory B Cell-Mediated Autoimmune Diseases, Immune Thrombocytopenia (ITP) | ||||
| Open drug page | |||||
In vivo CAR-T, target not disclosed |
Phase 1 | 31 Dec 2027Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma and 2 more | ||||
| Open drug page | |||||
In vivo CAR-T for blood cancers, target not disclosed |
Tcelltech · Private |
Phase 1 | 15 Oct 2028Phase 1 trial completes | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 15 Oct 2028 · Phase 1 trial completes | ||||
| Also tested for | Relapsed or Refractory Hematologic Malignancies | ||||
| Open drug page | |||||
In vivo CLL-1 CAR-T, lentiviral |
Phase 1 | 31 Oct 2028Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 Oct 2028 · Phase 1 trial completes | ||||
| Also tested for | Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | ||||
| Open drug page | |||||
In vivo CD19 CAR-T, lentiviral |
Umoja Biopharma · Private |
Phase 1 | Mar 2029Phase 1 trial completes | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | Mar 2029 · Phase 1 trial completes | ||||
| Also tested for | Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL) and 2 more | ||||
| Open drug page | |||||
In vivo CAR-T (CD19, BCMA and CD70 CARs), lentiviral |
Early Phase 1 | 30 May 2029Early Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 30 May 2029 · Early Phase 1 trial completes | ||||
| Also tested for | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia and 1 more | ||||
| Open drug page | |||||
In vivo CD19 CAR-T |
Bristol Myers Squibb · Public BMY |
Phase 1 | 20 Oct 2032Phase 1 trial completes | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 20 Oct 2032 · Phase 1 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Sjögren's Disease and 4 more | ||||
| Open drug page | |||||
In vivo CD20 CAR (T and NK cells), lentiviral |
Gilead (Kite) · Public GILD |
Phase 1 | — | ||
| How it works | Reprograms the patient's own immune T cells | ||||
| Also tested for | Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Matches
- Conditions, trial titles, drug names and codes, other names, how it works and company.
- Checked
- 16 of 16 drugs. How we check
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · openFDA updated 13 Nov 2026 · Company press releases
Ask your AI about this landscape. Connect it once, then ask in plain English.
Connect your AI
Which companies run in vivo CAR-T trials, and in which countries?Which should we check next?
Need a landscape built for you? Talk to us.
